H.C. Wainwright initiated coverage on Virax Biolabs Group Limited (NASDAQ:VRAX), a U.K.-based company focused on detecting ...

Virax Biolabs (VRAX) has started enrolling patients into its United Kingdom based, multi-center clinical study. Conducted in collaboration with ...

The latest update is out from Virax Biolabs Group Ltd. Class A ( ($VRAX) ). On March 18, 2025, Virax Biolabs Group Limited announced the ...

Virax Biolabs Group Limited is currently developing T cell-based test technologies with the intention of providing an immunology profiling platform. T cell testing can be particularly effective in ...

Virax Biolabs begins enrolling patients in clinical study assessing T cell dysfunction in post-acute infection syndromes: London Wednesday, March 19, 2025, 16:00 Hrs [IST] Virax B ...

Virax Biolabs Group Limited (NASDAQ: VRAX) ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today ...

Astellas Pharma and Yaskawa have agreed to form a JV that will focus on developing a cell therapy product manufacturing platform.

Officials at ARM, ASGCT, and ISCT convened a small group of scientists, policy experts, religious leaders and patient ...

Using an unbiased approach, this important study discovered a role of Ezh2 in the differentiation of granule neuron precursors, the cell of origin for Shh group of medulloblastoma. Furthermore, the ...